US20180055872A1 - Composition Comprising Neoagarooligosaccharide As Active Ingredient, For Prevention or Treatment of Sepsis or Septic Shock - Google Patents
Composition Comprising Neoagarooligosaccharide As Active Ingredient, For Prevention or Treatment of Sepsis or Septic Shock Download PDFInfo
- Publication number
- US20180055872A1 US20180055872A1 US15/541,231 US201515541231A US2018055872A1 US 20180055872 A1 US20180055872 A1 US 20180055872A1 US 201515541231 A US201515541231 A US 201515541231A US 2018055872 A1 US2018055872 A1 US 2018055872A1
- Authority
- US
- United States
- Prior art keywords
- neoagarooligosaccharide
- sepsis
- composition
- pharmaceutical composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 43
- 239000004480 active ingredient Substances 0.000 title claims abstract description 18
- 206010040070 Septic Shock Diseases 0.000 title claims abstract description 15
- 230000036303 septic shock Effects 0.000 title claims abstract description 15
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 title claims abstract description 13
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 30
- 241000534414 Anotopterus nikparini Species 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 229920001817 Agar Polymers 0.000 claims description 19
- 238000006911 enzymatic reaction Methods 0.000 claims description 18
- 229920000936 Agarose Polymers 0.000 claims description 17
- 239000008272 agar Substances 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 15
- 238000002649 immunization Methods 0.000 claims description 11
- 230000003053 immunization Effects 0.000 claims description 11
- 230000002787 reinforcement Effects 0.000 claims description 9
- JWMBOBQNPBCYER-UHFFFAOYSA-N 4-[(4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl)oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC1C(CO)OC(O)C(O)C1OC1C(O)C(C2O)OCC2O1 JWMBOBQNPBCYER-UHFFFAOYSA-N 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 241000187432 Streptomyces coelicolor Species 0.000 claims description 6
- XASQSRDYYCWSME-NWCCWNDLSA-N (2S,3R,4S,5R,6R)-4-[[(1S,3S,4S,5S,8R)-8-[(2S,3R,4S,5S,6R)-4-[[(1S,3S,4S,5R,8R)-4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O[C@@H]2O[C@H]3CO[C@H]([C@@H]3O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H]4O[C@H]5CO[C@H]([C@@H]5O)[C@@H]4O)[C@H]3O)[C@@H]2O)[C@@H]1O XASQSRDYYCWSME-NWCCWNDLSA-N 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 229920006008 lipopolysaccharide Polymers 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 101150005799 dagA gene Proteins 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 241000186361 Actinobacteria <class> Species 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 101710110830 Beta-agarase Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 108010045649 agarase Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- -1 olive oil Chemical compound 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241001446311 Streptomyces coelicolor A3(2) Species 0.000 description 3
- 241000187398 Streptomyces lividans Species 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WZYRMLAWNVOIEX-MOJAZDJTSA-N (2s)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetaldehyde Chemical compound O=C[C@@H](O)[C@@H]1OC[C@H](O)[C@H]1O WZYRMLAWNVOIEX-MOJAZDJTSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- DCQFFOLNJVGHLW-UHFFFAOYSA-N 4'-Me ether-Punctatin+ Natural products O1C(O)C(O)C2OCC1C2O DCQFFOLNJVGHLW-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- JPLATTLXZFUKRQ-UHFFFAOYSA-N Agarobiose Natural products OCC1OC(OC2C(O)COC2C(O)C=O)C(O)C(O)C1O JPLATTLXZFUKRQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101100055031 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) dagA gene Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- WZYRMLAWNVOIEX-UHFFFAOYSA-N cinnamtannin B-2 Natural products O=CC(O)C1OCC(O)C1O WZYRMLAWNVOIEX-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- WDMUXYQIMRDWRC-UHFFFAOYSA-N 2-hydroxy-3,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1O WDMUXYQIMRDWRC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000617590 Escherichia coli K1 Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 101710194220 Extracellular agarase Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000350481 Pterogyne nitens Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000828254 Streptomyces lividans TK24 Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/729—Agar; Agarose; Agaropectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01107—Diacylglycerol kinase (2.7.1.107)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a composition for prevention or treatment of sepsis or septic shock, in which the composition includes neoagarooligosaccharide as an active ingredient, and the neoagarooligosaccharide according to the present invention has an excellent effect in terms of immune enhancement by effectively suppressing inflammation, and also exhibits a good effect in preventing sepsis, and therefore can be effectively used in pharmaceuticals and functional foods for prevention or treatment of sepsis or septic shock and immune enhancement.
Description
- The present invention relates to a composition for prevention or treatment of sepsis or septic shock, in which the composition includes neoagarooligosaccharide as an active ingredient.
- For a long time, agar is a representative seaweed-derived polysaccharide which is widely used for food additives, medicines, cosmetics, livestock feed, and industrial raw materials. The agar is one of comparatively abundant fishery resources, and its yield is about 3,600 tons per year in Korea. However, only a portion of the total yield is simply processed in actual practice to be merely used as a cheap raw material, and the rest of the total yield went by wayside so that the added value is very low compared to the natural resource amount. Accordingly, there is great demand for development of a novel use of the abundant Korean agar or a study for the added value enhancement.
- The agar consists of agarose and agaropectin. The agarose is formed in a straight chain structure linked by α-1,3 bond, which is obtained by repeating agarobiose which is a monomer in which D-galactose and 3,6-anhydro-L-galactose are linked in β-1,4 bond so that the agarose's gel power is strong. On the other hand, the agaropectin is essentially composed of agarobiose units like agarose, but includes acidic group such as sulfuric acidic group so that the gel power thereof is weak.
- Among them, the agarose is digested into neoagarobiose via neoagarotetraose by β-agarase acting on β-1,4 bonds, and subsequently, is finally digested into D-galactose and 3,6-anhydro-L-galactose by α-agarase acting on the α-1, 3 bond.
- Meanwhile, streptomyces coelicolor A3 (2), actinomycetes, is known to produce an extracellular agarase (which is secreted out of cells) that digests agar (Stanier et al., 1942, J. Bacteriol.; Hodgson and Chater, 1981, J. Gen. Microbiol.). The agarase is encoded by a dagA gene. The dagA gene is a beta-agarase gene whose function is the only known in actinomycetes and plays an important role in the studies on agarase production in actinomycetes. In particular, the streptomyces coelicolor is the most widely used strain for the molecular biological study on actinomycetes, and the sequence of chromosomal DNA was analyzed and disclosed in the Sanger center in England in 2002.
- Meanwhile, sepsis is an inflammatory reaction induced when a pathogenic gram-negative bacterium infects a living body so that a lipopolysaccharide (LPS), a component of a cell wall, acts as a toxin to result in excessive activation of an immune system of a living body. Further, sepsis may cause infectious disease in the whole body or result in a shock when symptoms are severe. Specifically, sepsis is mainly occurred when patients with underlying diseases such as malignant tumor, leukemia, malignant lymphoma, acquired immunodeficiency syndrome (AIDS), collagen disease, renal failure, liver disease, cerebrovascular disorder, diabetes or hosts with humoral immunodeficiency or cellular immunodeficiency, whose resistance is weak, such as senior and premature infant, are subject to chemotherapy of adrenal steroids or anti-neoplastic, radiation therapy such as cobalt irradiation, or treatment and surgery such as indwelling catheter, hemodialysis, organ transplantation, and cardiac disease. Sepsis is a very serious disease with a mortality rate of more than 30%, which is the main cause of death of patients hospitalized in an intensive care unit. Despite medical technology's advance, many cases of sepsis occur still due to post-operative infection in worldwide, and many cases of sepsis occur when a person with weak immunity of the body, such as neonates or seniors, is infected. Typically, the birth sepsis is known to develop in about 3 of 1,000 mature infants, but premature infants are known to increase the attack rate by 3 to 4 times. When a patient has sepsis, the patient is usually treated with antibiotics. However, when microorganisms are proliferated since the suitable treatment is delayed, or when the infection is caused by a strain resistant to antibiotics, antibiotics only may not effectively treat the disease, and the number of pathogens resistant to various antibiotics is increasing. Thus, it is urgently needed to develop a novel therapeutic agent for sepsis
- The inventors of the present invention have extensively studied to meet the requirements. As a result, the inventors have found that agar-derived neoagarooligosaccharide prepared by the DagA enzyme reaction has excellent effects that not only inhibits the growth of bacteria, but also eliminates the endotoxin isolated from dead bacteria. Thus, it is used in combination with antibiotics so as to minimize the side effects caused by antibiotics and to have remarkably excellent effects of treating sepsis compared to the single administration therewith, thereby completing the present invention.
- An object of the present invention relates to a composition for prevention or treatment of sepsis or septic shock, in which the composition includes neoagarooligosaccharide as an active ingredient.
- Another object of the present invention relates to a composition for reinforcement of immunization, in which the composition includes neoagarooligosaccharide as an active ingredient.
- In order to address the issues as described above, the present invention provides a pharmaceutical composition for prevention or treatment of sepsis or septic shock, in which the pharmaceutical composition includes neoagarooligosaccharide as an active ingredient.
- Further, the present invention provides a food composition for prevention or amelioration of sepsis or septic shock, in which the food composition includes neoagarooligosaccharide as an active ingredient.
- Further, the present invention provides a pharmaceutical composition for reinforcement of immunization, in which the pharmaceutical composition includes neoagarooligosaccharide as an active ingredient.
- Further, the present invention provides a functional food for reinforcement of immunization, in which the functional food includes neoagarooligosaccharide as an active ingredient.
- Since the neoagarooligosaccharide according to the present invention shows excellent effects of not only preventing sepsis, but also enhancing immunity by effectively suppressing inflammation development, the neoagarooligosaccharide is useful for medicines and functional foods for prevention or treatment of sepsis or septic shock and reinforcement of immunization.
-
FIG. 1 shows a map of pUWL201pw vector. -
FIG. 2 shows a map of a recombination vector according to an embodiment of the present invention. -
FIG. 3 shows graphs illustrating results of an HPLC-ELSD analysis of an enzyme reaction product of the present invention. -
FIG. 4 is a graph showing the survival rate over time of animal models in which neoagarooligosaccharide of the present invention is pre-treated and sepsis is induced. -
FIG. 5 is a graph showing the secretion amount of inflammatory cytokines in the serum of animal models in which neoagarooligosaccharide of the present invention is pre-treated and sepsis is induced. -
FIG. 6 is a graph showing AST, ALT and BUN concentrations in the serum of animal models in which neoagarooligosaccharide of the present invention is pre-treated and sepsis is induced. -
FIG. 7 is a graph showing the survival rate of animal models in which neoagarooligosaccharide of the present invention is pre-treated and LPS is administered. -
FIG. 8 is a graph showing the secretion amount of inflammatory cytokine in serum of animal models in which neoagarooligosaccharide of the present invention is pre-treated and LPS is administered. -
FIG. 9 is a graph showing AST, ALT and BUN concentrations in the serum of animal models in which neoagarooligosaccharide of the present invention is pre-treated and LPS is administered. -
FIG. 10 is a graph showing the degree of infiltration of inflammatory inducing cells in the lung tissue of animal models in which neoagarooligosaccharide of the present invention is pre-treated and LPS is administered. -
FIG. 11 is a graph showing the degree of apoptosis in the splenic tissue of animal models in which neoagarooligosaccharide of the present invention is pre-treated and LPS is administered. - Hereinafter, the present invention will be described in detail.
- The present invention provides a composition for prevention or treatment of sepsis or septic shock, in which the composition includes neoagarooligosaccharide, which is prepared from agar or agarose by a DagA enzyme reaction, as an active ingredient.
- The composition includes a pharmaceutical composition and a food composition.
- DagA of the present invention is a β-agarase protein, which means the amino acid sequence of SEQ ID NO: 2. DagA includes a protein produced from streptomyces coelicolor which is actinomycetes, or a heterologous strain. Further, DagA includes a recombinant protein according to conventional gene recombinant methods within the range that the function is not changed to be completely different or the beta-agarase activity is not lost, i.e., a method of including a labeled amino acid for advantageous purification, modifying the amino acid sequence for heterologous expression, etc.
- More specifically, DagA of the present invention is produced with a molecular weight of about 35 kDa, having 309 amino acids of SEQ ID NO: 2 when it is translated from a gene of beta-agarase prepared by streptomyces coelicolor. DaeA is secreted in the form of the completed extracellular protein (about 32 kDa) in which 30 N-terminal amino acid signal peptides are cleaved to have the amino acid sequence 31 to 309 of SEQ ID NO: 2.
- The dagA gene of streptomyces coelicolor may encode the DagA, and the dagA gene may be represented by the nucleotide sequence of SEQ ID NO: 1. SEQ ID NO: 1 is the nucleotide sequence of the gene present in the genome of streptomyces coelicolor A3 (2) and is named “SCO3471” on database of National Center for Biotechnology Information (NCBI) in U.S. As confirmed through in vitro experiments, the transcription of the dagA gene is regulated by 4 or 5 other promoters that are recognized by at least 3 other holoenzymes of the RNA polymerase. Through an analysis of transcription step of the dagA gene, the transcription was shown to be initiated at the 32nd, 77th, 125th, and 220th bases of the encoding sequence.
- DagA of the present invention may be prepared through the culture of streptomyces coelicolor, which is a producing strain of DagA, but the expression system of streptomyces lividans, a heterologous strain is preferably used to increase production efficiency. A method is used in which the dagA gene is inserted into a vector for actinomyces to prepare a recombinant vector, then streptomyces lividans is transformed with the recombinant vector, and then the transformant is cultured. In this case, the recombinant vector is preferably configured in which the transcription of the dagA gene can be regulated by a promoter derived from actinomycetes.
- When preparing the recombinant vector, the promoter derived from actinomycetes can be selected and used since the promoter derived from actinomycetes includes various promoters such as a sgtR promoter (sgtRp), an ermE promoter (ermEp), and a tipA promoter (tipAp). Several kinds of vectors configured in which the transcription may be regulated by these promoters have been developed so that SCO3471 is cloned into this vector to produce a recombinant vector having a structure in which the transcription is regulated by the promoter derived from actinomycetes.
- A host strain may be transformed with a recombinant vector to prepare the transformant. Since there are various methods for transformation according to the host strain, an appropriate method can be selected and used. For example, when streptomyces lividans is used as a host strain, a transformation method can use PEG (polyethylene glycol) as a medium.
- A DagA producing strain such as a transformant may be cultured in a liquid medium to prepare DagA. High purity DagA can be prepared using a conventional protein purification method such as ultrafiltration for the obtained culture medium. At this time, agar or agarose is included in the liquid medium so as to prepare DagA more efficiently.
- The polysaccharide such as agar and agarose may be converted into relatively small oligosaccharides through the enzyme reaction of DagA. The enzyme reaction is preferably performed at a temperature of 35° C. to 45° C. and a pH of 6 to 8, but is not limited thereto.
- The neoagarooligosaccharide is prepared as a product obtained by the enzyme reaction, and the neoagarooligosaccharide may be each of neoagarobiose, neoagarotetraose, and neoagarohexaose, and they may be in a mixed state thereof, but is not limited thereto.
- The neoagarooligosaccharide according to the present invention shows preventive or therapeutic effects of sepsis by reducing pro-inflammatory cytokines, increasing anti-inflammatory cytokines, and significantly lowering the mortality due to sepsis or septic shock.
- In the present invention, “sepsis” refers to a state in which infection causes a serious inflammatory reaction with a microorganism in a whole body. Systemic inflammatory response syndrome (SIRS) is called when there are two or more kinds of symptoms such as fever with body temperature of 38° C. or more, hypothermia down to 36° C., respiratory rate increased more than 24 times per minute (tachypnea), at least 90 heartbeats per minute (tachycardia), and an increase or marked decrease in leukocyte count on the blood test. Sepsis is called when the systemic inflammatory response syndrome is caused by microbial infection. Pathogens consistently or intermittently enter the bloodstream from the body's infectious focuses, settle in various organs, create lesions, and show severe systemic symptoms. The causative bacteria include staphylococcus, streptococcus, escherichia coli, pseudomonas aeruginosa, mycobacterium tuberculosis, pneumococcus, fungus, and anaerobic bacteria.
- Further, the present invention provides a composition for reinforcement of immunization, in which the composition includes neoagarooligosaccharide, which is prepared from agar or agarose by a DagA enzyme reaction, as an active ingredient.
- The composition includes a pharmaceutical composition and a health supplement food.
- The neoagarooligosaccharide according to the present invention exhibits an effect of reinforcement of immunization by inhibiting the secretion of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory cytokines.
- The composition may be used for an immunological disease or the prevention of the immunological disease. The immunological disease includes various inflammatory diseases, allergic diseases and cancers caused by abnormal immune system of living body. Examples of the immunological diseases include cold, asthma, pneumonia, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, allergies, rheumatoid arthritis, Alzheimer's disease, autoimmune thyroid disease, inflammatory bowel disease, aplastic anemia, lupus erythematosus, and psoriasis, but are not limited thereto.
- Since the neoagarooligosaccharide according to the present invention shows excellent effects of not only preventing sepsis, but also enhancing immunity, the neoagarooligosaccharide is useful for medicines and functional foods for prevention or treatment of sepsis or septic shock and reinforcement of immunization.
- The composition of the present invention may further include suitable carriers, excipients, and diluents which are conventionally used in the preparation of pharmaceutical compositions. The pharmaceutical composition according to the present invention may be formulated and used in the form of oral formulations, external preparations, suppositories, and sterilized injections such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols. Suitable formulations known in the art may preferably include those disclosed in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton Pa.
- The pharmaceutical composition of the present invention may include carriers, excipients and diluents such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- When the pharmaceutical composition of the present invention is formulated, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants which are usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like. These solid formulations may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral administration may include suspensions, solutions, emulsions, syrups and the like, and may include various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like in addition to water and liquid paraffin which are simple diluents commonly used. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried formulations, and suppositories. The non-aqueous solvent and suspension may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Bases of suppository may include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
- The term “administration” as used herein refers to provide any composition of the present invention to a subject in any suitable manner.
- The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and body weight of the subject, the degree of disease, the type of drug, the administration route, and the period of time, but may be appropriately selected by those skilled in the art. In order for a desired effect, the composition of the present invention may be administered at 0.001 mg/kg to 1000 mg/kg per one day. The administration may be carried out once a day or divided into several times. The dose does not limit the scope of the present invention in any way.
- The pharmaceutical composition of the present invention may be administered to a subject through various pathways. All ways of administration may be expected to include, for example, oral, rectal or intravenous, intramuscular, subcutaneous, uterine duramater, or intracerebral injection administration. The pharmaceutical composition of the present invention may preferably be administered in the form of an injection.
- The pharmaceutical composition according to the present invention may further include the above-mentioned effective ingredient as well as at least one known substance having effects of preventing or treating sepsis or septic shock or enhancing immunization.
- The pharmaceutical composition according to the present invention may further include a bronchodilator, an antihistamine agent or an anti-inflammatory agent in addition to the above-mentioned active ingredients.
- For example, the bronchodilator may include β-agonist, an anticholinergic agent, a methylantanine, etc. The antihistamines may include acrivastine, cetirizine, desloratadine, fexofenadine, levocertirizine, loratadine, mizolastine, ailmemazine, chlocertirizine, clemastine, cypropheptadine, hydroxyzine, ketotifen, promenthazine, and the like. The anti-inflammatory agent may include aspirin, diclofenac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, naproxen, piroxicam, sulindac, celecoxib, valdecoxib, rofecoxib, and the like.
- In the present invention, the term “functional food” refers to a food group in which food is imparted with added value to allow the function of the food to function or express for particular purpose using physical, biochemical, biotechnological techniques or the like, or food which is designed and manufactured so that the body control function related to the regulation of the bio-defense rhythm of the food composition, disease prevention and recovery, etc. is sufficiently expressed in the living body.
- The functional food may include a food supplement additive which is acceptable in sitology, and may further include suitable carriers, excipients and diluents conventionally used in the production of functional foods.
- When the composition of the present invention is used as a food additive, the composition may be added individually or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (e.g., prevention, health or therapeutic treatment). In the production of food or beverage, the composition of the present invention is generally added in an amount of 15% or less by weight, preferably 10% or less by weight based on the raw material. However, it may be less than the above range on long-term intake for the purpose of health and hygiene, or for the purpose of controlling health. The active ingredient may be used in an amount exceeding the above range due to no problem in aspects of safety.
- In addition to the above, the composition of the present invention may further include various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salt, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonates, and the like. In addition, the composition of the present invention may include flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives does not matter, but is generally selected in the range of 0.01 parts by weight to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
- Hereinafter, the present invention will be described in more detail with reference to Embodiments. However, it should be noted that the following Embodiments are provided to illustrate the present invention to allow a more easily understanding, but the present invention is not limited to Embodiments.
- PCR was carried out using the following Asm-F and Asm-R primers with the chromosomal DNA of streptomyces coelicolor A3 (2) as a template to amplify a dagA gene fragment (a 947 bp fragment in which a signal peptide and a complete peptide of DagA were encoded, and a partial sequence of the primer was included in SEQ ID NO: 1). The dagA gene was cloned into the pUWL201pw vector shown in
FIG. 1 using the restriction enzyme site (NdeI/BamHI) of the fragment, and thus a recombinant vector was prepared such that the transcription of the dagA gene was regulated by the ermE promoter. Such configuration is illustrated inFIG. 2 . -
Asm-F primer: (SEQ ID NO: 3) 5′-GACATATGGTGGTCAACCGACGTGATC-3′ (NdeI) Asm-R primer: (SEQ ID NO: 4) 5′-GGTGGATCCCTACACGGCCTGATACG-3′ (BamHI) - The transformant strain obtained by transforming streptomyces lividans TK24 with the recombinant vector was used for the preparation of DagA.
- The strain was inoculated on R2YE liquid medium containing 0.3% (w/v) of agar and cultured and shaken at 120 rpm and 28° C. for 48 hours to 72 hours. After the pre-culture, the culture was performed, and each time of the culture was 2.5 days. The culture solution obtained through the culture was centrifuged to remove microbial cells, and the supernatant was filtered through an ultrafiltration membrane (5 kDa cut-off membrane) to isolate and purify proteins that did not pass through the filtration membrane. The obtained concentrate (enzyme solution) was used while being stored by freeze drying.
- The agarase activity of DagA in
Embodiment 1 was measured using estimation of reducing sugar by DNS method. 0.5 ml of a 20 mM Tris-HCl solution (pH 7) containing 0.5% (w/v) of agarose was mixed with 10 μl of the enzyme solution obtained inEmbodiment 1, and the mixture was reacted at 40° C. for 15 minutes. Then, 0.5 ml of DNS reagent (dinitrosalicylic acid 6.5 G, 2M NaOH 325 ml, glycerol 45 ml/1 l distilled water) was added thereto, and the mixture was boiled for 10 minutes. Then, the mixture was cooled, and the absorbance thereof was measured at Å540 nm. 1 U of the enzyme was defined as an activity that shows an absorbance (Å540 nm) of 0.001 after 15 minutes of reaction. - 1 L of a 20 mM Tris-HCl solution in which 0.5% to 5% (w/v) of agar or agarose was dissolved was prepared and heated at 100° C. for about 10 minutes to dissolve it sufficiently. Then, the mixture was cooled down to 40° C. and then was treated with 2,000 U to 50,000 U of DagA enzyme to perform the enzyme reaction for 24 hours.
- In order to remove undegraded agarose from the enzyme reaction product, supernatant was recollected by centrifugation, and then the enzyme reaction product was confirmed using thin layer chromatography (TLC). The recollected supernatant was partially purified by ultrafiltration with a 5 kDa cut-off membrane.
- HPLC-ELSD analysis was performed to confirm the composition of the enzyme reaction product obtained in Embodiment 3 as described above. NH2 P-50 4E multimode column (250×4.6 mm) was used, and a mixed solution of acetonitrile and water (acetonitrile:water=65:35) was used as a mobile phase. The result is illustrated in
FIG. 3 . - As shown in
FIG. 3 , the total amount of neoagarooligosaccharides composed of neoagarobiose (hereinafter referred to as “DP2”), neoagarotetraose (hereinafter referred to as “DP4”), and neoagarohexaose (hereinafter referred to as “DP4”) of the reaction products was showed to account for 65±20% (by weight). DP2, DP4, and DP6 respectively were showed to account for 0% to 10%, 50% to 70%, and 30% to 50% (by weight) based on the total amount of the neoagarooligosaccharides. - In order to analyze the preventive effect of neoagarooligosaccharide administration on sepsis, the following experiment was conducted.
- 1-1. Experimental Design and Survival Rate Analysis
- Six-week-old female BALB/c mice were used as experimental animals. The mice were pretreated intraperitoneally with neoagarooligosaccharide on mouse abdomen. One hour later, 107 CFU/mice of E. coli K1 (dissolved in LB broth) was injected to induce sepsis.
FIG. 4 shows the survival rate over time of each mouse in the experimental group and the control group in which sepsis was induced. - As shown in
FIG. 4 , the control group died 18 hours after the induction of sepsis. On the other hand, the survival rate of the group which was pretreated with neoagarooligosaccharide was significantly increased compared to that of the control group. - 1-2. Analysis of Serum
- The serum was separated from each
mouse 12 hours after the induction of sepsis to analyze levels of inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-12p70, and IL-10), AST, ALT, and BUN, respectively, in the serum. At this time, the concentration of the cytokine was measured using an ELISA kit (eBiosciences, San Diego, Calif.), and the result are shown inFIGS. 5 and 6 . - As shown in
FIG. 5 , when pre-treated with neoagarooligosaccharide, the amounts of TNF-α, IL-6, IL-1β and IL-12p70, which are pro-inflammatory cytokines increased by sepsis in the mouse serum, were significantly inhibited. On the other hand, the secretion of IL-10, an anti-inflammatory cytokine, was increased by pre-treatment of neoagarooligosaccharide. - Further, as shown in
FIG. 6 , the concentrations of AST, ALT, and BUN in the serum, which were associated with hepatic and renal toxicity, were increased by sepsis, but were significantly inhibited when the mouse was pre-treated with neoagarooligosaccharide. - In order to analyze the effect of neoagarooligosaccharide on the immunity enhancement, the following experiment was performed.
- 2-1. Experimental Design and Survival Rate Analysis
- Six-week-old female BALB/c mice were used as experimental animals. The mice were pretreated intraperitoneally with 100 mg/kg of neoagarooligosaccharide on mouse abdomen and injected with 20 mg/kg of lipopolysaccharide (LPS) after one hour.
FIG. 7 shows the survival rate over time of each mouse in the experimental group and the control group. - As shown in
FIG. 7 , the control group died 24 hours after administration of LPS. On the other hand, the survival rate of the group pretreated with neoagarooligosaccharide was significantly increased compared to that of the control group. The survival rate was increased depending on the concentration of neoagarooligosaccharide. - 2-2. Analysis of Serum
- The serum was separated from each
mouse 12 hours after LPS administration to analyze levels of inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-12p70, and IL-10), AST, ALT, and BUN, respectively, in the serum. At this time, the concentrations of the cytokines were measured using an ELISA kit (eBiosciences, San Diego, Calif.), and the result are shown inFIGS. 8 and 9 . - As shown in
FIG. 8 , when pre-treated with neoagarooligosaccharide, the amounts of TNF-α, IL-6, IL-1β, and IL-12p70, which are pro-inflammatory cytokines increased by LPS administration in the mouse serum, were significantly inhibited. On the other hand, the secretion of IL-10, an anti-inflammatory cytokine, was increased by pre-treatment of neoagarooligosaccharide. - Further, as shown in
FIG. 9 , the concentrations of AST, ALT, and BUN in the serum, which were associated with hepatic and renal toxicity, were increased by sepsis, but were significantly decreased when the mouse was pre-treated with neoagarooligosaccharide. - 2-3. Analysis of Organization
- The lung and spleen tissues were extracted from each mouse after 12 hours of the administration of LPS. Paraffin section and H&E staining were performed according to a conventionally known method to observe them through a microscope. The results are shown in
FIGS. 10 and 11 . - As shown in
FIG. 10 , the infiltration of inflammatory cells in the lung tissue, in which the neoagarooligosaccharide was pretreated was significantly inhibited compared to that of the control group. - Further, as shown in
FIG. 11 , cell death in the spleen tissue, in which the neoagarooligosaccharide was pretreated was significantly inhibited compared to that of the control group. - Through the experimental results, it was confirmed that the neoagarooligosaccharide has excellent effects of preventing sepsis and septic shock and reinforcing immunization by effectively suppressing the expression of inflammation.
- Hereinafter, formulation examples of the pharmaceutical composition and the food composition of the present invention will be described, but the present invention is not limited thereto, but is specifically described.
- 1-1. Preparation of Powder
- 20 mg of neoagarooligosaccharide
- 100 mg of lactose
- 10 mg of talc
- The components were mixed and packed in an airtight bag so as to prepare powders.
- 1-2. Preparation of Tablet
- 10 mg of neoagarooligosaccharide
- 100 mg of corn starch
- 100 mg of lactose
- 2 mg of magnesium stearate
- The components were mixed and tableted according to a conventional method of preparing tablets so as to prepare tablets.
- 1-3. Preparation of Capsule
- 10 mg of neoagarooligosaccharide
- 3 mg of crystalline cellulose
- 14.8 mg of lactose
- 0.2 mg of magnesium stearate
- The components were mixed and filled in gelatin capsules according to a conventional method of preparing capsules so as to prepare capsules.
- 1-4. Preparation of Injection
- 10 mg of neoagarooligosaccharide
- 180 mg of Mannitol
- 2974 mg of sterilized water for injection
- 26 mg of Na2HPO4.2H2O
- According to a conventional method of preparing injections, 2 ml per ample was prepared as an amount of the components.
- 1-5. Preparation of Liquid Agent
- 10 mg of neoagarooligosaccharide
- 10 g of isomerized glucose
- 5 g of mannitol
- appropriate amount of purified water
- According to a conventional method of preparing liquid agents, each component was added and dissolved in the purified water, and the lemon flavor was added in an appropriate amount. Then, the components were mixed, and then the purified water was added thereto. The whole mixture was then adjusted to 100 ml by adding the purified water and was filled in a brown bottle. Then the mixture was sterilized to prepare liquid agents.
- 2-1. Preparation of Health Food
- 100 mg of neoagarooligosaccharide
- appropriate amount of vitamin mixture
- 70 g of vitamin A acetate
- 1.0 mg of vitamin E
- 0.13 mg of vitamin B1
- 0.15 mg of vitamin B2
- 0.5 mg of vitamin B6
- 0.2 g of vitamin B12
- 10 mg of vitamin C
- 10 g of biotin
- 1.7 mg of nicotinic acid amide
- 50 g of Folic acid
- 0.5 mg of calcium pantothenate
- appropriate amount of inorganic mixture
- 1.75 mg of ferrous sulfate
- 0.82 mg of zinc oxide
- 25.3 mg of magnesium carbonate
- 15 mg of potassium phosphate monobasic
- 55 mg of potassium phosphate dibasic
- 90 mg of potassium citrate
- 100 mg of calcium carbonate
- 24.8 mg of magnesium chloride
- Although the composition ratio of the vitamin and mineral mixture is configured to be mixed with comparatively suitable ingredients for health food, the composition ratio may be arbitrarily modified. After the components were mixed according to conventional methods of preparing health foods, granules were prepared and used in the preparation of a health food composition according to conventional methods.
Claims (9)
1. A pharmaceutical composition for prevention or treatment of sepsis or septic shock, the pharmaceutical composition comprising neoagarooligosaccharide, which is prepared from agar or agarose by a DagA enzyme reaction, as an active ingredient.
2. The pharmaceutical composition of claim 1 , wherein the DagA enzyme is derived from Streptomyces coelicolor.
3. The pharmaceutical composition of claim 2 , wherein the DagA enzyme is represented by amino acid sequences 31 to 309 of SEQ ID NO: 2.
4. The pharmaceutical composition of claim 2 , wherein the DagA enzyme is encoded by a nucleotide sequence of SEQ ID NO: 1.
5. The pharmaceutical composition of claim 1 , wherein the enzyme reaction is carried out at a temperature of 35° C. to 45° C. and pH of 6 to 8.
6. The pharmaceutical composition of claim 1 , wherein the neoagarooligosaccharide is one or more kinds selected from the group consisting of neoagarobiose, neoagarotetraose, and neoagarohexaose.
7. A food composition for prevention or ameliorating sepsis or septic shock, the food composition comprising neoagarooligosaccharide prepared from agar or agarose by DagA enzyme reaction as an active ingredient.
8. A pharmaceutical composition for reinforcement of immunization, the pharmaceutical composition comprising neoagarooligosaccharide prepared from agar or agarose by a DagA enzyme reaction, as an active ingredient.
9. A functional food for reinforcement of immunization, the functional food comprising neoagarooligosaccharide prepared from agar or agarose by a DagA enzyme reaction, as an active ingredient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140194174A KR101675359B1 (en) | 2014-12-30 | 2014-12-30 | Composition comprising neoagarooligosaccharide for preventing or treating sepsis or septic shock |
KR10-2014-0194174 | 2014-12-30 | ||
PCT/KR2015/009485 WO2016108394A1 (en) | 2014-12-30 | 2015-09-09 | Composition comprising neoagarooligosaccharide as active ingredient, for prevention or treatment of sepsis or septic shock |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/009485 A-371-Of-International WO2016108394A1 (en) | 2014-12-30 | 2015-09-09 | Composition comprising neoagarooligosaccharide as active ingredient, for prevention or treatment of sepsis or septic shock |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/383,311 Division US10548916B2 (en) | 2014-12-30 | 2019-04-12 | Composition comprising neoagarooligosaccharide as active ingredient, for prevention or treatment of sepsis or septic shock |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180055872A1 true US20180055872A1 (en) | 2018-03-01 |
Family
ID=56284512
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/541,231 Abandoned US20180055872A1 (en) | 2014-12-30 | 2015-09-09 | Composition Comprising Neoagarooligosaccharide As Active Ingredient, For Prevention or Treatment of Sepsis or Septic Shock |
US16/383,311 Active US10548916B2 (en) | 2014-12-30 | 2019-04-12 | Composition comprising neoagarooligosaccharide as active ingredient, for prevention or treatment of sepsis or septic shock |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/383,311 Active US10548916B2 (en) | 2014-12-30 | 2019-04-12 | Composition comprising neoagarooligosaccharide as active ingredient, for prevention or treatment of sepsis or septic shock |
Country Status (4)
Country | Link |
---|---|
US (2) | US20180055872A1 (en) |
KR (1) | KR101675359B1 (en) |
CN (1) | CN107206018B (en) |
WO (1) | WO2016108394A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10933086B2 (en) * | 2016-10-27 | 2021-03-02 | Dynebio Inc. | Composition for preventing, alleviating, or treating arthritis or osteoporosis, containing neoagarooligosaccharide |
US11413305B2 (en) * | 2017-11-28 | 2022-08-16 | Korea University Research And Business Foundation | Use of agar-derived oligosaccharides for inhibiting growth of Staphylococcus |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102208956B1 (en) * | 2018-03-26 | 2021-01-28 | 한국생명공학연구원 | DEVELOPMENT OF TECHNOLOGY FOR INDUCING AN OVEREXPRESSION OF β-AGARASE DagA ENZYME |
CN110317846A (en) * | 2019-07-19 | 2019-10-11 | 中国海洋大学 | A method of preparing odd number fine jade oligosaccharides |
KR102549630B1 (en) * | 2022-08-02 | 2023-07-03 | 경북대학교 산학협력단 | METHOD FOR AGAROSE LIQUEFACTION AND NA4/NA6 PRODUCTION USING THERMOSTABLE GH6B β-AGARASE DERIVED FROM A NOVEL AGAR-DEGRADING BACTERIUM |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5418156A (en) * | 1991-04-15 | 1995-05-23 | University Of Maryland | Agarase enzyme system from alteromonas strain 2-40 |
US20050020526A1 (en) * | 2003-06-03 | 2005-01-27 | Cytogenix, Inc. | Oligodeoxynucleotide intervention for prevention and treatment of sepsis |
US20040248101A1 (en) * | 2003-06-03 | 2004-12-09 | Cytogenix, Inc. | Identification of novel antibacteria agents by screening the single-stranded DNA expression library |
CN101636686A (en) | 2007-03-01 | 2010-01-27 | Jsr株式会社 | Liquid crystal aligning agent and liquid crystal display |
WO2011050126A1 (en) * | 2009-10-21 | 2011-04-28 | University Of Medicine And Dentistry Of New Jersey | Method for treating sepsis or septic shock |
KR101206006B1 (en) * | 2010-12-31 | 2012-11-28 | 신라대학교 산학협력단 | Strain of flammeovirga sp. having a agar-decomposition activity and method of producing agarooligosaccharides using the same |
KR101294380B1 (en) | 2011-07-28 | 2013-08-08 | 엘지이노텍 주식회사 | Impedance matching apparatus and impedance matching method |
WO2014077575A1 (en) * | 2012-11-13 | 2014-05-22 | 다인바이오 주식회사 | Agar-derived neoagarooligosaccharide composite composition prepared by daga enzyme reaction and having anti-obesity and anti-diabetes effects |
KR101632262B1 (en) * | 2012-11-13 | 2016-06-21 | 다인바이오 주식회사 | Agar-derived neoagarooligosaccharide complex for the prevention and treatment of obesity and/or diabetes comprising enzyme reaction products of beta agarase DagA and agar |
-
2014
- 2014-12-30 KR KR1020140194174A patent/KR101675359B1/en active IP Right Grant
-
2015
- 2015-09-09 WO PCT/KR2015/009485 patent/WO2016108394A1/en active Application Filing
- 2015-09-09 US US15/541,231 patent/US20180055872A1/en not_active Abandoned
- 2015-09-09 CN CN201580075360.0A patent/CN107206018B/en active Active
-
2019
- 2019-04-12 US US16/383,311 patent/US10548916B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10933086B2 (en) * | 2016-10-27 | 2021-03-02 | Dynebio Inc. | Composition for preventing, alleviating, or treating arthritis or osteoporosis, containing neoagarooligosaccharide |
US11413305B2 (en) * | 2017-11-28 | 2022-08-16 | Korea University Research And Business Foundation | Use of agar-derived oligosaccharides for inhibiting growth of Staphylococcus |
Also Published As
Publication number | Publication date |
---|---|
KR101675359B1 (en) | 2016-11-14 |
KR101675359B9 (en) | 2022-09-20 |
CN107206018B (en) | 2020-06-26 |
CN107206018A (en) | 2017-09-26 |
WO2016108394A1 (en) | 2016-07-07 |
US10548916B2 (en) | 2020-02-04 |
US20190290678A1 (en) | 2019-09-26 |
KR20160083329A (en) | 2016-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10548916B2 (en) | Composition comprising neoagarooligosaccharide as active ingredient, for prevention or treatment of sepsis or septic shock | |
JP6815525B2 (en) | Compositions for the prevention, amelioration or treatment of arthritis or osteoporosis containing neoagalooligosaccharides | |
KR102283127B1 (en) | A composition for improving liver function comprising genus Leuconostoc | |
KR102543494B1 (en) | Novel probiotics and use thereof | |
KR102526564B1 (en) | Composition for preventing or treating inflammatory disease comprising Lactibacillus sakei CVL-001 strain | |
KR20160020457A (en) | Composition for enhancing immune function or anticancer effect comprising neoagarooligosaccharide | |
JP2012180329A (en) | Promoter for production and secretion of antimicrobial substance | |
JP4426506B2 (en) | New lactic acid bacteria and beverages using new lactic acid bacteria | |
KR102486028B1 (en) | Composition for preventing, treating or improving bone diseases containing extracellular vesicles derived from Lactobacillus sakei CVL001 strain culture medium | |
KR101632262B1 (en) | Agar-derived neoagarooligosaccharide complex for the prevention and treatment of obesity and/or diabetes comprising enzyme reaction products of beta agarase DagA and agar | |
KR20180087662A (en) | A pharmaceutical composition comprising cystatin and protein derived from lactic acid bacteria | |
KR102539772B1 (en) | Lactococcus lactis strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof | |
JP3995733B2 (en) | Immunostimulatory composition | |
US20110268829A1 (en) | Quality of life for hepatitis c patients with a formulation for administration to the oral mucosa including lactobacillus delbrueckii subsp. bulgaricus and n-acetyl d-glucosamine | |
EP3845237A2 (en) | Use of recombinant antibacterial protein ablysin for effectively killing multidrug-resistant pathogenic bacteria | |
WO2010008113A1 (en) | Anti-cancer composition comprising a culture fluid of lactobacillus casei as an effective component | |
KR102048434B1 (en) | A composition as a prebiotic for improving intestinal microflora containing High-molecular fraction from radish leave | |
KR20180046021A (en) | Composition including neoagarooligosaccharide for preventing, improving or treating inflammatory disease | |
KR101923062B1 (en) | Composition including neoagarooligosaccharide for preventing, improving or treating osteoporosis | |
EP4324842A1 (en) | Signal sequence that induces protein secretion in intestinal microbiome | |
KR101353563B1 (en) | Composition for stimulating immune response comprising bacterial proteoglycan from Rahnella aquatilis | |
KR102244732B1 (en) | Probiotic acetic acid bacteria Acetobacter pasteurianus MGLV and its immunomodulatory effect | |
KR20180046392A (en) | Composition including neoagarooligosaccharide for preventing, improving or treating arthritis | |
KR101473423B1 (en) | Lactic acid bacteria ferment of Oyaksoonki-san having anti-hypertension effects and use thereof | |
JP2009254236A (en) | New lactic acid bacterium and food, drink and immunostimulator using new lactic acid bacterium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DYNEBIO INC., KOREA, DEMOCRATIC PEOPLE'S REPUBLIC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, E HYEON;LEE, MOON HEE;HONG, SUN JOO;AND OTHERS;REEL/FRAME:043348/0182 Effective date: 20170726 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |